Loading patent…
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Universite De Paris, Medecine Et Innovation, Fonds De La Recherche Scientifique - Fnrs
InventorsDaniel ZAGURY, Hélène LE BUANEC, Armand BENSUSSAN, Charles CASSIUS
Estimating the term…
Among regulatory T cells, natural regulatory T cells (nTregs) ensure the control of self-tolerance and are currently tested in clinical trials in autoimmune diseases and allogeneic hematopoietic stem cell transplantation. Here the inventors show that based on CD39/CD26 markers, the human nTreg population is comprised of 5 major cell subsets each representing a distinct state of maturation. Phenotypic and genetic characteristics of the subsets illustrate the structural parental maturation between subsets which further correlates with expression of regulatory factors. Importantly, the inventors also show that blood nTreg CD39/CD26 profile, remaining constant over a 2year period in healthy persons but varying between individuals, represents a novel biomarker for monitoring chronic diseases, as illustrated in their preliminary study on AI (dermatomyositis, rheumatoid arthritis and leukemias). Accordingly, the present invention relates to the use of CD26 and CD39 as phenotypic markers for assessing maturation of natural Treg cells.
A population of Foxp3+ T cells selected from the group consisting of:
(canceled)
A method of assessing the maturation stage of a population of Foxp3+ T cells comprising i) detecting the expression of the phenotypic markers CD45RA, CD25, CD26 and CD39 in said population of Foxp3+ T cells and ii) determining a category of maturation stage to which said population of Foxp3+ T cells belongs.
(canceled)
A method of determining whether a patient suffering from cancer is eligible for treatment with a CD39 inhibitor and if so, treating the patient with the CD39 inhibitor comprising i) quantifying the amount of a population of CD39+ cells selected from the group consisting of selected from the group consisting of:
A kit comprising a panel of antibodies specific for CD3, CD4, CD8, Foxp3, CD25, CD45RA, CD26 and CD39.
Dependencies are inferred from the claim text.